All Posts Tagged With: "ALXN"
(ALXN) Alexion Pharmaceuticals – Bull of the Day
We are upgrading Alexion Pharmaceuticals (ALXN) to Outperform from Neutral on valuation grounds; we believe that there is significant upside scope from current levels. Alexion performed very well in the final...
(ALXN) Alexion Pharmaceuticals – Bull of the Day
Alexion Pharmaceuticals’ (ALXN) third quarter 2011 adjusted earnings of $0.32 per share breezed past the Zacks Consensus Estimate by $0.09 and the year-ago adjusted earnings by $0.11. Results were driven...
(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11
While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500.
Thus, by the end of the week we...
(ALXA) Company News for October 5, 2011 – Corporate Summary
• Drug developer Transcept Pharmaceuticals Inc.’s (NASDAQ:TSPT) shares increased 33.77% to close at $8.08 after the company’s experimental sleep treatment got approved from the regulators
• ...
(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11
Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are...
(ALXN) Alexion Pharmaceuticals Stands at Neutral
We are maintaining our Neutral stance on Alexion Pharmaceuticals (ALXN) with a target price of $49.00.
Alexion Pharma delivered a strong performance in the first quarter of 2011. First quarter earnings...
(ALXN) Alexion Pharmaceuticals Hears Good News for New Drug Application
Recently, Alexion Pharmaceuticals (ALXN) received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its New Drug Application (NDA) of Soliris (eculizumab). The company was seeking...
(PDLI) PDL BioPharma’s Fourth Quarter Falls Short
PDL BioPharma, Inc. (PDLI) reported fourth-quarter fiscal 2009 earnings of 17 cents per share, 2 cents below the Zacks Consensus Estimate. The company earned 34 cents (from continuing operations) in the year-ago...
(ALXN) Alexion Pharmaceuticals Beats Earnings Estimates by a Penny
Alexion Pharmaceuticals Inc. (ALXN) reported fourth quarter earnings per share (EPS) of 25 cents, a cent above the Zacks Consensus Estimate and well above 17 cents reported in the year-ago...
(ALXN) Alexion Pharmaceutical’s Plant Gets Positive Opinion
Alexion Pharmaceutical’s (ALXN) Rhode Island manufacturing facility (ARIMF) should be up and running shortly as a second source of supply for the drug Soliris (eculizumab). The company recently received...
(ALXN) Alexion Pharmaceuticals Beats, Raises Outlook
Yesterday, Alexion Pharmaceuticals (ALXN) came out with strong third quarter financials. The company reported earnings per share of 29 cents, well above the Zacks Consensus Estimate of 21 cents and 23 cents...